Clinical Performance of the Checkable Medical At-Home Strep A Test

Sponsor
Checkable Medical Inc (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05107362
Collaborator
Curebase (Other)
1,000
8
18.3
125
6.8

Study Details

Study Description

Brief Summary

The Checkable Medical At-Home Strep A Test is a rapid chromatographic immunoassay for the qualitative detection of Group A Strep (GAS) antigens from throat swabs. The purpose of the study is to evaluate the clinical performance of the investigational device (i.e., sensitivity, specificity, NPV and PPV) when used by untrained lay persons to detect the presence of Group A Streptococcal antigens in throat swab specimens from individuals five years of age and older with signs and symptoms of pharyngitis, such as fever and sore throat.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: untrained lay user performs investigational diagnostic test

Detailed Description

The study is a prospective, consecutive, non-interventional multicenter study to evaluate the clinical performance of the Checkable Medical At-Home Strep A Test when the test is performed by non-trained adult lay users.

  1. Patients or parents/legal guardians of patients presenting with signs and symptoms of pharyngeal GAS infections will be recruited at primary care or urgent care clinics.

  2. Informed consent will be obtained from adult subjects and from the parents/guardians of pediatric subjects. Pediatric subjects 7 years of age or greater will be asked for their assent.

  3. The lay user will be provided with a Checkable Medical At-Home Strep A Test kit. The user and patient will be provided with a quiet, private space where the user can collect the throat swab specimen and perform the investigational test.

  4. Once the lay user has collected the swab sample for the Checkable Medical At-Home Strep A Test and performed the test, she/he will document the test result. The Checkable Medical At-Home Strep A Test result is not to be shared with members of the site team who are providing healthcare to the subject.

  5. When all sample collection, testing and interpretation activities related to the investigational test are completed, a healthcare provider at the study site will collect two additional swab samples. One of these samples will be sent to a central lab where it will be cultured for GAS. An additional sample will be tested using the organization's standard of care (SOC) rapid Strep A test.

  6. Subjects will be diagnosed and treated in accordance with routine SOC which may include an FDA-cleared rapid GAS test. The Checkable Medical At-Home Strep A Test will not be used to diagnose or treat study subjects.

  7. This study will take place in at least six sites in at least three different regions of the United States.

  8. The results from the Checkable Medical At-Home Strep A Test will be used to compare with the diagnostic truth obtained through culture to compute diagnostic accuracy parameters including sensitivity, NPV, specificity and PPV.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Clinical Performance of the Checkable Medical At-Home Strep A Test
Actual Study Start Date :
Dec 21, 2021
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Symptomatic Adult and Pediatric Subjects

Untrained lay user to collect throat swab specimen and perform investigational test.

Diagnostic Test: untrained lay user performs investigational diagnostic test
Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.

Outcome Measures

Primary Outcome Measures

  1. Clinical Sensitivity and Clinical Specificity [1 day]

    Sensitivity is the proportion of subjects with a positive bacterial culture that are also positive in the investigational Strep A test (+). Specificity is the proportion of subjects with a negative bacterial culture that are also negative in the investigational Strep A test (-).

Secondary Outcome Measures

  1. Negative Predictive Value [1 day]

    Negative Predictive Value (NPV) is the proportion of subjects with negative investigational Strep A test results who also have negative cultures (diagnostic truth); calculated as 100 x d/(c+d).

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subjects seeking medical care for two or more of the following signs/symptoms of pharyngeal streptococcal infections:
  • pharyngeal pain [with or without swallowing],

  • tonsillar swelling with exudates,

  • pharyngeal erythema,

  • tender cervical lymphadenopathy,

  • fever.

  1. Subjects who have not received antibiotic treatment within the past 14 days.

  2. Subjects (or their parents/guardians) provide written informed consent/assent to participate in the study

Exclusion Criteria:
  1. Lay users who are accompanying patients are unwilling/unable to collect throat swab sample from a child or adult.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Robertson Pediatrics Beverly Hills California United States 90211
2 Angel Kids Pediatrics Jacksonville Florida United States 32225
3 AFC Urgent Care Bronx New York United States 10465
4 Plains Clinical Research Fargo North Dakota United States 58104
5 AFC Urgent Care Easley South Carolina United States 29640
6 Pediatric Associates Houston Texas United States 77087
7 Santa Clara Family Clinic Houston Texas United States 77087
8 North Houston Internal Medicine and Pediatric Clinic Tomball Texas United States 77375

Sponsors and Collaborators

  • Checkable Medical Inc
  • Curebase

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Checkable Medical Inc
ClinicalTrials.gov Identifier:
NCT05107362
Other Study ID Numbers:
  • CM-003
First Posted:
Nov 4, 2021
Last Update Posted:
Jul 20, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Checkable Medical Inc
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022